stockrow
Saturday 7 November 2026
Export BCTX’s income statement to Excel — free account
BRIACELL THERAP
BCTX Healthcare Biotechnology
- EPS
- +110.2%
- Free cash flow
- +26.7%
Quarter to July 2026, against a year earlier
4.00
0.73
+22.32%
Follow BCTX
Alert me
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(439.51%) | (177.26%) | (173.55%) | (212.23%) | |
| (244.43%) | (137.98%) | (139.20%) | (154.34%) | ||
ROIC |
0.00% | (6,192.94%) | (3,311.00%) | 0.00% | |
Return on Tangible Assets |
(345.68%) | (101.34%) | (138.48%) | (242.68%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(15.35) | (11.05) | (4.33) | (5.83) | |
Free Cash Flow |
(28.92) | (30.97) | (31.41) | (29.24) | |
Capital Expenditures |
— | — | (0.58) | (0.58) | |
| Other line items | |||||
Cash ROIC |
(148.11%) | (51.51%) | (67.96%) | (80.98%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | 137.34 | 97.29 | — | |
Operating CF/Net income |
1.01 | 1.04 | 1.00 | 0.82 | |
Depreciation/Fixed assets |
0.39 | 0.42 | 0.32 | 0.37 | |
Capex/Depreciation |
0.00 | 0.00 | (5.17) | (4.89) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(15.35) | (11.05) | (4.25) | (5.72) | |
Capex per Share |
0.00 | 0.00 | (0.08) | (0.12) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026